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AbstrACt
Objectives The interaction between the immune system 
and tumor cells is an important feature for the prognosis 
and treatment of cancer. Multiplex immunohistochemistry 
(mIHC) and multiplex immunofluorescence (mIF) 
analyses are emerging technologies that can be used 
to help quantify immune cell subsets, their functional 
state, and their spatial arrangement within the tumor 
microenvironment.
Methods The Society for Immunotherapy of Cancer (SITC) 
convened a task force of pathologists and laboratory 
leaders from academic centers as well as experts from 
pharmaceutical and diagnostic companies to develop best 
practice guidelines for the optimization and validation of 
mIHC/mIF assays across platforms.
results Representative outputs and the advantages 
and disadvantages of mIHC/mIF approaches, such 
as multiplexed chromogenic IHC, multiplexed 
immunohistochemical consecutive staining on single 
slide, mIF (including multispectral approaches), tissue- 
based mass spectrometry, and digital spatial profiling are 
discussed.
Conclusions mIHC/mIF technologies are becoming 
standard tools for biomarker studies and are likely to 
enter routine clinical practice in the near future. Careful 
assay optimization and validation will help ensure outputs 
are robust and comparable across laboratories as well 
as potentially across mIHC/mIF platforms. Quantitative 
image analysis of mIHC/mIF output and data management 
considerations will be addressed in a complementary 
manuscript from this task force.
bACkgrOund
The tumor microenvironment (TME) 
represents a complex interaction between 
elements of the host and tumor cells. It 
includes a variety of immune cells (T- lympho-
cytes and B- lymphocytes, natural killer cells, 
dendritic cells, and different myeloid cell 
types like macrophages and granulocytes), 
characterized by specific immunoactive 
protein expression patterns (e.g. immune 
checkpoints such as programmed cell death 
protein-1 (PD-1)/programmed cell death 
ligand 1 (PD- L1), cytokines such as inter-
feron gamma), and stromal cells (blood 
vessels and fibroblasts), each representing a 
potentially unique niche. Early characteriza-
tion of some of these elements, such as PD- L1 
expression by tumor and/or immune cells 
or density of pre- existing CD8+, T cell infil-
trates in pretreatment tumor specimens, have 
been correlated with responses to immune 
checkpoint blockade.1–4 Additionally, studies 
of on- treatment specimens have helped char-
acterize how immunotherapy exposure can 
remodel the tumor immune microenviron-
ment, providing important insights into the 
mechanism of action of these agents and early 
markers of therapeutic efficacy.3 5–10 Based on 
these early successes, there is great interest 
in characterizing an expanded number of 
TME features, with the aim of identifying new 
robust biomarkers that can be used to drive 
precision medicine approaches.
The biomarkers with greatest clinical utility 
currently are derived from profiling cells that 
are directly associated with the tumor.11 Char-
acterization of peripheral blood immune 
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cells correlates poorly with the composition of cells in 
the TME and as such, studies on peripheral blood have 
provided limited value to date in selecting patients likely 
to benefit from cancer immunotherapy. Studies of tumor 
specimens are also associated with their own challenges, 
including: limited tissue availability, variation in tissue 
handling prior to paraffin embedding, spatial heteroge-
neity of marker expression, and challenges surrounding 
the detection of complex or rare cell phenotypes in situ. 
Flow cytometry is a robust approach to cellular pheno-
typing, but the requirement for fresh tissue, the low cell 
yield, and the loss of spatial information limits the routine 
application of such methods.12
Multiomic DNA and RNA approaches such as those 
used in the TCGA project have provided large datasets 
for explorations of tumor taxonomy as well as the prog-
nostic significance of immune infiltrates.13 14 The input 
for these assays is heterogeneous, in that the samples 
include all the TME cells in addition to some proportion 
of non- tumor tissue. Although bioinformatic/computa-
tional approaches have been used to deconvolute mRNA 
expression data, so that individual cell types can be virtu-
ally profiled in silico,15 16 much information about spatial 
context is lost with these methods. Similarly, single- cell 
RNA- seq allows for the characterization of the expression 
profile of individual cells and lacks spatial information. In 
contrast, immunohistochemistry (IHC) can distinguish 
between different cell types expressing the same protein 
and can characterize the density and spatial distribution 
of specific cells within the TME. IHC can also provide a 
semi- quantitative assessment of marker intensity. Immu-
nofluorescence (IF) has the additional benefit of being 
able to characterize a large dynamic range of expression 
on a cell- by- cell basis. A recent meta- analysis comparing 
tumor mutational burden, gene expression profiling 
for interferon- gamma gene signatures, PD- L1 IHC, and 
multiplex IF (mIF)/multiplex IHC (mIHC) approaches 
showed that mIF/mIHC had significantly higher perfor-
mance than the other approaches for predicting objec-
tive response to anti- PD- (L)1 therapies.17 These findings 
underscore the potential biomarker value of co- expres-
sion and spatial distribution metrics.
The key component of both IHC and IF assays are 
specific antibodies that detect a single protein of interest. 
This antibody is typically visualized via enzyme- mediated 
indirect labeling or through a direct conjugate of a 
chromogen or fluorophore to the primary antibody. 
The most widely used approach for both clinical and 
research settings is an IHC assay designed to identify a 
single protein in a section from formalin- fixed paraffin- 
embedded (FFPE) tissue that is then interpreted by a 
pathologist using brightfield microscopy. Newer tech-
nologies allow for the simultaneous targeting of multiple 
proteins in a single assay, commonly referred to as mIHC 
or mIF.
Multiplexing approaches can analyze the cells of a tissue 
and demonstrate 2–50 markers expressed on a single cell 
level with high precision and accuracy.18–20 mIHC can be 
performed by either adding multiple labels (e.g., Ventana- 
RocheTM or Biocare MedicalTM) to the slide at one time, 
or by using a stain and strip or cycling approach. Multiple 
platforms exist for mIF techniques, including standard IF 
scopes which can support 4–5 plex assays, and multispec-
tral technologies (Vectra 3.0TM/PolarisTM), which can 
support 6–8- plex assays. Higher- order plex approaches 
include multiplex ion beam imaging, by time of flight 
(MIBI- TOF), imaging mass cytometry (IMC), and digital 
spatial profiling (DSP), among others. The basic prin-
ciples underpinning these different approaches will 
be discussed here, as will the advantages and disadvan-
tages of each (summarized in table 1). Importantly, each 
approach requires optimization and validation.21 Here, 
we present general recommendations that represent 
current consensus opinions for minimum best practice 
requirements to ensure quality data results. Importantly, 
the data generated by these approaches represent the end 
product of the assay, and of the imaging and associated 
analysis of the quantitative data, as all these methods typi-
cally require the use of digital images analysis. Imaging, 
image analysis, and related topics will be covered in a 
separate publication.
Antibody selection
The most critical component of any IHC/IF assay is the 
primary antibody targeting the biomarker of interest. 
Monoclonal antibodies are often preferred due to their 
higher specificity and reproducibility, and because 
they are almost always generated to unique peptides of 
the target antigen, that is, peptides that are generally 
located in regions less affected by formalin fixation (as 
in cytoplasmic tails and linear loops, avoiding secondary 
structures).
When evaluating which primary antibody could be 
leveraged in an IHC/IF assay, the potential impact of 
antibody sensitivity and specificity must be considered. 
These characteristics may be provided by the antibody 
suppliers; however, the accuracy of vendor recommen-
dations for antibody use should be verified by the user. 
The importance of understanding antibody specificity 
has been widely discussed in the scientific community. 
Journal editorials have been written alerting readers 
to the limited characterization of antibodies that were 
utilized in many prior publications.22–25
Antibody specificity may be established using a variety 
of methods. Cell lines that are transfected with the 
biomarker or are known to spontaneously express the 
target provide essential controls to determine, as a first 
pass, the specificity of the antibody. Ideally, the antibody 
should be tested on cells transfected with the target of 
interest, in cell line knockdowns to remove target expres-
sion, and in cells that are transfected with different mole-
cules of the same family to further demonstrate specificity 
(e.g. an antibody to PD- L1 should identify cells trans-
fected with PD- L1 but not with PD- L2 or B7- H4). However, 
pure cell line preparations do not contain the multitude 
of proteins that are encountered in the intended- for- use 
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sample (e.g. a tumor biopsy, with tumor cells, stroma, 
blood vessels, inflammatory cells, secreted proteins, 
extracellular matrix, etc.). The specificity of antibodies 
needs to be further tested in tissues, ideally in a range 
of normal and diseased tissues. Unexpected staining in 
particular cells can be confirmed with an orthogonal 
method, such as in situ hybridization, to confirm the 
RNA expression of the target on the same cells as those 
identified by the antibody. If there is a disconnect, it is 
mostly likely due to nonspecific binding of the antibody 
to some other molecule in the tissue. Further specificity 
may be demonstrated by replacing the primary antibody 
with an isotype control used at the same concentration. 
This highlights any potential non- specific background 
of the assay system. The best method to prove specificity 
is using two monoclonal antibodies to adjacent but non- 
overlapping epitopes. Then, IHC testing of both anti-
bodies on tissue microarrays (TMAs) with 30–50 tissues 
of interest is followed by quantitative measurement and 
regression. This method controls for all potential tissue 
cross- reactivity, but is often prohibitively expensive.
Antibody sensitivity is best established using cell lines 
that express the target at different levels (ideally with the 
number of molecules per cell determined by flow cytom-
etry). This approach can also help define the dynamic 
range of the assay. In practice, such resources are not always 
available for the marker of interest. Alternate approaches 
including testing multiple antibodies to ensure robust 
performance and/or comparison to previously reported 
or anticipated staining patterns are commonly used, 
although not ideal. One strategy for maximizing target 
signal is through pooling of various antibodies for the 
detection of a target, such as the pooling of various anti-
cytokeratins to detect total cytokeratin. This can also be 
used to conduct broad phenotyping. For example, if one 
were interested in the quantification of macrophages, 
one could pool CD68, CD163, and CD11b into one fluo-
rescent marker, and effectively one fluorescent channel. 
Sensitivity may also be assessed by orthogonal methods.25
Finally, a key issue in antibody validation is reproduc-
ibility. Vendors frequently provide monoclonal antibodies 
at different concentrations and sometimes without speci-
fying concentration, as if they were polyclonal. The anti-
body concentration of polyclonal antibodies is unknown, 
which led to the practice of using a given dilution, rather 
than an absolute protein concentration. When using 
monoclonal antibodies, methods sections should specify 
antibody concentrations (in µg/mL) for better repro-
ducibility. Additionally, assay development for multisite 
clinical trials and/or routine clinical use should include 
quantitative reproducibility studies using different lots of 
the antibody from the vendor and different operators. 
This is often performed on a small index TMA of 30–50 
cases.
Controls for assay development and performance
At a minimum, positive and negative controls for a given 
marker should be run with each staining batch, and 
Clinical Laboratory Improvement Amendments (CLIA) 
recommendations include positive controls that are on 
the same slide as the tissue being tested.26 In many cases, 
a single piece of tissue, for example, normal tonsil, can 
serve as both a positive and negative control, by studying 
anticipated staining patterns. For example, PD- L1 expres-
sion is expected in the crypt epithelium, tingible- body 
macrophages and other follicular histiocytes, and scat-
tered interfollicular macrophages and rare lymphocytes, 
while other cells are expected to be negative.
TMAs also provide an opportunity to use a number 
of different normal and tumor tissues as assay controls, 
potentially representing a range of expression for the 
marker of interest. Normal tissues are often preferen-
tially employed, as they can be procured easily in large 
amounts from surgical specimens. Some groups have also 
developed approaches whereby these two strategies are 
combined, for example, TMA cores embedded in spleen 
or tonsil tissue (online supplementary figure 1). Batch- to- 
batch quantitation of expression for a given marker in the 
control tissue can provide an early indication of reagent 
degradation as well as an opportunity for normalization 
of quantitative read- outs across batches.
As described above, cell lines are useful in determining 
optimal antibody concentration but should also be tested 
alongside FFPE tissues with cells known to be positive 
and negative in expression. This is because cell lines are 
designed to overexpress the protein of interest, and it is 
possible that if assays are only optimized to cell lines, the 
assay may not be sensitive enough to detect potentially 
lower levels of expression observed in tissue.
standard chromogenic IHC (single marker and mIHC)
Assay principles and workflow
Standard chromogenic IHC methods have been widely 
used in pathology laboratories for decades. Despite some 
drawbacks, it has been extremely useful in diagnostic and 
research settings, and pathologists are very familiar with 
the methodology, staining characteristics, and interpreta-
tion. In addition, companion diagnostic tests have been 
developed based on standard chromogenic IHC tests, 
such as those for HER2/neu and PD- L1. While most chro-
mogenic IHCs tend to be single stains, it is possible to 
perform multiple chromogenic IHCs on the same slide 
with different chromogens, that is, chromogenic mIHC.
The critical first step in any IHC assay in FFPE tissues 
is developing proper assay conditions that expose anti-
gens often affected by formalin fixation, to improve their 
detection by the antibody. A variety of these ‘epitope 
retrieval’ conditions have been developed over the years 
and have been reviewed elsewhere.27–30 The methods 
generally revolve around applying energy to the tissue 
(typically in the form of heat) in the presence of a solu-
tion of buffers that denature the proteins, remove meth-
ylene bridges caused by formalin, and reducing chemical 
forces that could potentially interfere with the anti-
body binding to the target antigen. In most automated 
staining platforms, antigen retrieval conditions have been 
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Figure 1 Light microscopy multiplex chromogenic 
immunohistochemistry staining. Representative image of 
triplex FOXP3/CD8/KRT staining with purple (Discovery 
HRP, Ventana, Roche Tissue Diagnostics), yellow (Discovery 
AP, Ventana, Roche Tissue Diagnostics) and teal (Discovery 
HRP, Ventana, Roche Tissue Diagnostics) chromogens and a 
hematoxylin counterstain.
standardized—most platforms offer two standard options 
of buffers to be tested (typically one based on a citrate 
buffer, and the other on a high pH buffer containing 
EDTA). In any method development process, a variety of 
antigen retrieval conditions can be tested to identify the 
optimal conditions for a given target.
Once the epitope of interest is properly exposed, two 
blocking steps are performed to prevent non- specific 
staining. The first, in horseradish peroxidase (HRP)- 
based detection systems, is a peroxidase block. Perox-
idase blocking is especially important on tissues with 
abundant red blood cells or numerous myeloid cells like 
bone marrow and spleen, and organs like the kidney that 
express abundant endogenous peroxidase that can poten-
tially catalyze peroxidase- driven chromogenic reactions 
on non- specific targets. Some authors have noted that the 
concentration of peroxidase block should be decreased 
for some antibodies like anti- CD4 and anti- CD45, due to 
potential loss of stain intensity.31 The second blocking 
step is the application of serum- free protein, which 
prevents non- specific binding of antibodies to a tissue or 
Fc receptor.
After blocking, the antibody of interest is added. The 
primary antibody should be titrated to an appropriate 
concentration that retains the specificity of the stain, while 
removing any background signal or non- specific staining 
(‘blush’) of the tissue. Antibodies used at too high of a 
concentration can result in off- target staining.32–35 While 
determination of signal to noise ‘by eye’ is often used, to 
be rigorous, this should be done quantitatively.33 Signal- 
to- noise maxima can be identified by assessing a small 
series of tumors across multiple primary antibody concen-
trations. Use of antibodies at that optimal concentration 
results in better accuracy and reproducibility.34
The visualization of the primary antibody’s labeling 
of tissue is accomplished through a secondary antibody 
link, with or without amplification, followed by a detec-
tion system. The most commonly used amplification 
systems currently are polymer- based. They are typically 
anti- mouse and/or anti- rabbit polymer with several HRP 
enzymes bound to the polymer. These have the potential 
to significantly amplify signal without the background 
staining observed historically with avidin- biotin systems. 
The drawback to polymers is that their formula is propri-
etary, so they are often different lengths with varying 
numbers of bound HRPs. Care should be taken in 
selecting the appropriate polymer as different polymers 
can affect assay sensitivity. Additionally, steric hindrance 
may affect the performance of some of the larger poly-
mers, depending on antigen size and location.
For chromogenic assays, the traditional detection system 
is 3,3′-diaminobenzidine, which is oxidized by hydrogen 
peroxide, and precipitates as a brown color on the tissue. 
3- Amino-9- ethylcarbazole (AEC) is also commonly used. 
It precipitates as a red color and can be removed using 
organic solvents. There has been a surge of new chro-
mogens recently, which are substrates of either HRP or 
alkaline phosphatase, enzymes typically used in detection 
systems. These colors include purple, red, teal, yellow, 
green, blue, and silver, and they offer an opportunity to 
perform multiplexing using chromogenic IHC, especially 
in those cases where the biomarkers of interest are not 
on the same cells (figure 1). In some instances, unique 
combinations of these chromogens even allow for iden-
tification of co- expression of biomarkers in a single cell 
due to color shifts when the two chromogens are super-
imposed (e.g. yellow chromogen on top of a purple chro-
mogen yields an orange color that can be differentiated 
from the pure yellow and purple colors).
The final steps involve counterstaining and coverslip 
application. Hematoxylin is the most routinely used 
counterstain. If the detection system is alcohol soluble, 
it is important to choose a hematoxylin and an acid 
rinsing/blueing protocol that does not contain ethanol, 
for example, Gill’s and Mayer’s hematoxylin. Similarly, 
the mounting media used for coverslipping should be 
compatible with the detection system. For example, 
routinely used mounting media usually requires xylene, 
however, xylene can alter aqueous chromogens such as 
AEC.
Assay optimization and validation
In addition to selection and optimization of the primary 
antibody, as described above, conditions that need to be 
optimized include antibody incubation times and the 
amplification method. The overarching theme of all 
assay optimization is to increase the signal- to- noise ratio. 
This may be achieved in a number of ways, for example, 
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by extending the antibody incubation time, which may 
allow for a lower primary antibody concentration while 
maintaining the stain specificity. If the signal is too low or 
the assay is not sensitive enough, extending the antigen 
retrieval time and/or time of exposure to the polymer 
amplification may be of benefit, although care must be 
taken to avoid non- specific staining. If signal- to- noise 
ratio becomes an issue for a low- level expressing marker, 
a tyramide signal amplification (TSA) approach may help 
(see ‘Multiplex immunofluorescence’ section). All these 
conditions need to be tested and optimized for a single 
assay, and one frequently adopted approach is the use 
of a ‘matrix system’ to cover multiple conditions in one 
assay run, thus eliminating any variation that may be seen 
between runs. When the aim is to combine multiple single 
chromogenic IHCs into an mIHC, it is important to opti-
mize assay conditions to facilitate the multiplex combi-
nation, for example, having common epitope retrieval 
conditions for all targets.
Clinical assay validation recommendations have been 
extensively reviewed and are covered in guidelines from 
the College of American Pathologists (CAP).36–38 Gener-
ally, for an IHC assay to be considered validated, at a 
minimum, it needs to be shown to be accurate (specific 
and sensitive) and precise, and reproducible from an 
analytic perspective (intrarun, inter- run, interinstru-
ment, interlot, and interoperator variability), and from 
a pathologist interpretation perspective (interpathologist 
scoring reproducibility). Ultimately, the assay needs to 
be shown to be reproducible between different labora-
tories (interlaboratory reproducibility). Known factors 
affecting epitope integrity, and therefore intralaboratory 
and interlaboratory reproducibility for a given marker, 
also include preanalytical variables such as tissue isch-
emia, fixation time, and storage conditions (temperature, 
duration, and format, e.g. whether stored as a tissue block 
or slide). There are less well- cataloged requirements for 
non- clinical assays in the research setting.
Advantages
The advantages to chromogenic IHC are that it is a rela-
tively easy, inexpensive, and established technique that 
has defined standards and guidelines, for example, the 
National Institute of Health Cancer Therapy Evaluation 
Program39 and CAP guidelines. Multiple reagents and 
automated platforms are available, and their perfor-
mance has been well characterized. The stains are most 
often read using light microscopy, which allows for easier 
quality oversight than many fluorescent methods, since 
most pathologists are more familiar with light micros-
copy, including the handling and storage of the slides. 
Additionally, high- throughput brightfield digital image 
acquisition platforms are available, and in some instances 
are being integrated into routine clinical workflows.
Disadvantages
Multiplexing is relatively difficult using chromogenic 
approaches. This is because when multiple chromogenic 
stains are performed simultaneously on a single slide, 
there are only a few existing chromogens that are very 
effective in allowing for the study of marker co- expres-
sion. The dynamic range of marker intensity is also 
limited, and thus chromogenic stains are most often used 
to simply assess expression as positive versus negative, or 
a semi- quantitative H- score.40
Multiplexed immunohistochemical consecutive staining on 
single slide
Assay principles and workflow
Multiplexed immunohistochemical consecutive staining 
on single slide (MICSSS), as the name suggests, relies 
on iterative cycles of immunostaining on a single slide 
and shares many steps with single chromogenic IHC 
stains.41 42 In brief, a whole- slide scanner scans the slide 
after each staining cycle, followed by manual coverslip 
removal, chromogenic enzyme substrate removal, and 
proper blocking steps, before another single IHC stain is 
applied (figure 2).
MICSSS has some specific requirements beyond those 
for single IHC staining. First, the enzyme substrates must 
be soluble, for example, in ethanol, in order to be able 
to remove the chromogen for the next staining cycle. 
AEC is often used for this purpose, since it is compatible 
with HRP, however there are many other options with 
different colors available. Before each immunostaining 
cycle, chemical destaining is used to strip the chromogen 
and the antigen retrieval is repeated. Additional steps and 
associated reagents may also be required to ensure that 
the primary antibody is either completely removed or 
blocked. Several methods have been described including 
glycine- sodium dodecyl sulfate (SDS), potassium perman-
ganate (KMnO4), and Fab blocking for eluting antibodies 
in sequential immunostaining approaches.43 Fab frag-
ment blocking (e.g. donkey anti- mouse Fab fragment in 
order to block primary antibodies raised in mouse) is the 
primary antibody block of choice for the MICSSS method 
in order to prevent any staining interference when a 
primary antibody raised in the same species is used in 
previous immunostaining cycles.44
Assay optimization and validation
Despite the fact that most of the antibodies in a vali-
dated and optimized MICSSS antibody inventory allow 
them to be performed in different orders in a selected 
multiplex panel, new markers require an extensive 
and labor- intensive validation testing process.45 Each 
new marker must be optimized as a single IHC marker, 
that is, a ‘singleplex’ stain, and they must be tested in 
different orders to demonstrate qualitative and quantita-
tive antigen signal preservation. Some epitopes preserve 
their antigen signal even after 10 immunostaining cycles, 
whereas some are sensitive to the stripping process and 
should be prioritized so as to be exposed to only a few 
or no antibody stripping steps. Whenever a new marker 
is added or substituted in an MICSSS panel, a de novo 
comparison of all markers to their IHC single stain as 
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Figure 2 Light microscopy multiplexed immunohistochemical consecutive staining on single slide (MICSSS). (A) As the name 
suggests, MICSSS uses iterative cycles of tagging, image scanning, and destaining of chromogenic substrate on a single slide 
to generate a multiplex image. (B) Representative triple negative breast cancer tissue specimen stained for FOXP3, DC- LAMP, 
CD163, CD20, CD8 and CD3. Upper panels show each individual chromogenic stain. The lower panel shows the resultant 
composite image that has been pseudo- colored for fluorescence. HIER, Heat- induced epitope retrieval; HRP, horseradish 
peroxidase; QC, quality control.
well as permutations of order testing is essential to ensure 
the assay’s sensitivity and specificity is maintained. This is 
sufficiently subtle that quantitative assessment is required 
for accuracy.
Advantages
Like other chromogenic IHC approaches, MICSSS is 
relatively simple and affordable. It requires a brightfield 
microscope and scanner, which are more commonly 
available than IF- based instrumentations. The fact that 
each marker is labeled individually on the slide reduces 
some of the risks of steric hindrance and other types of 
staining or signal interference (see ‘blocking’/’umbrella 
effect’ and ‘bleed- through’ in ‘Multiplex immunofluores-
cence’ section). MICSSS also allows for the whole slide 
to be studied for each marker. This is a key distinction 
from other multiplex methods like multiplex spectral 
imaging,46 IMC,47 and DSP, whereby only a few selected 
regions of interest (ROIs) are typically studied (figure 3).
Disadvantages
The major disadvantages to MICSSS are that it is a 
time- consuming technique when compared with other 
high- throughput/multiplexing methods, and that it 
requires careful handling over many immunostaining 
and scanning cycles. For example, a 10- marker MICSSS 
panel requires 10 cycles of immunostaining/scanning, 
with each cycle taking 1–2 days. Although it is rare, the 
repeated coverslip removal can potentially contribute to 
tissue artifacts. Such alterations have downstream effects 
on all subsequent staining cycles and during image anal-
ysis. It can also be challenging to manipulate the order of 
staining so that antigens sensitive to cycling are measured 
first.
Merging individual MICSSS whole slide images in 
order to create a multiplex whole slide image for analysis 
is another challenge. Software is used for image align-
ment/registration of the sequential tissue scans48–52 to 
minimize and correct for potential microscopic changes 
on the tissue section that occur after each cycle and/or 
movement of the slide within the scanner rack. Image 
analysis will be discussed in a separate manuscript, but 
in brief, MICSSS whole- slide images are red- green- blue 
(RGB)- type, and they cannot be merged in their original 
RGB format. Image processing steps are needed to create 
a multiplexed multicolor image after image registration, 
including color deconvolution, color inversion (pseudo-
fluorescence), and a final merging of images.
Multiplex immunofluorescence
Assay principles and workflow
The basic principle of mIF (a.k.a. QIF, for quantitative 
immunofluorescence) is that multiple protein targets 
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Figure 3 Imaging area varies by the multiplex immunohistochemistry (mIHC)/multiplex immunofluorescence (mIF) approach. 
Representative slide from a malignant melanoma showing the relative area of regions of interest (ROIs) acquired for analysis by 
each technology. It is possible to acquire adjacent ROIs such that the entire tumor is profiled using mIF, digital spatial profiling 
(DSP), or mass spectrometry. This latter approach currently requires consideration for acquisition time, data management, and 
analysis. For example, chromogenic IHC with light microscopy requires approximately 2–4 min to acquire a whole slide image, 
while each ROI for mass spectrometry requires 15–120 min, depending on the platform used and desired resolution (see online 
supplementary table 1). MICSSS, multiplexed immunohistochemical consecutive staining on single slide.
can each be stained by specific antibodies labeled with 
distinct fluorophores. When excited, the fluorophores 
emit at a characteristic wavelength. A microscope with 
specific bandpass filter sets is used to collect signal from 
these well- defined emission spectra. The IF fluorophores 
have a large dynamic range, and thus IF staining of tissue 
has the power to phenotypically characterize cells, akin 
to flow cytometry. Yet, unlike flow cytometry, the signal is 
captured in situ, facilitating spatial studies. Importantly, 
the intrinsic fluorescence spectra from FFPE tissue can 
overlap with the antibody- reporter systems, meaning 
that antibody- specific signal needs to be distinguished 
from FFPE tissue autofluorescence. Autofluorescence 
was historically thought to prevent fluorescent imaging 
on FFPE tissue, but antigen retrieval methods combined 
with the selection of fluorophores with peak emission 
away from the autofluorescence peak (around 490 nm) 
allowed immunofluorescence studies as early as the late 
90s.53
Primary antibody visualization in mIF can be achieved 
through direct or indirect fluorophore labeling, both of 
which use wavelengths between ~350 nm and ~750 nm 
(primarily in the visible light spectrum). Antibodies can 
be labeled using quantum dots,43 44 DNA barcodes,54 and 
reactive fluorophores, among others. One of the most 
widely used approaches for mIF is an indirect approach 
that employs TSA.19 This method provides signal ampli-
fication through a polymer- HRP detection system 
combined with activation of tyramide fluorophores. The 
activated tyramide covalently binds to tyrosine residues 
on and surrounding the epitope of interest. Heat is 
then used to remove the non- covalently bound primary 
antibody for that target and polymer- HRP, while the 
tyramide- linked fluorophore remains deposited on the 
tissue. Another primary antibody to the next target can 
then be applied to the tissue and visualized by a different 
tyramide- linked fluorophore. The cyclical staining and 
amplification is then repeated, as necessary, with consid-
eration given to the order of antigen measurement to 
ensure optimal epitope detection. Using this approach, it 
is possible to create a protocol that can allow researchers 
to use antibodies raised in the same species and create 
panels that can accommodate simultaneous detection of 
up to six to eight individual targets (figure 4). Emerging 
studies suggest that it may be possible to increase this 
number to ~30–60 individual mIF targets using a cyclic 
staining approach where non- TSA- based, low- plex fluo-
rescence assays are cycled on the same sample and then 
assembled using image analysis algorithms,54–56 similar to 
what is done for MCISSS.
The number of targets that can be visualized simultane-
ously using mIF is limited by the number of wavelength 
band passes and paired excitation/emission filter sets. 
If the spectral profiles of the fluorophores are too close 
in wavelength, the risk is so- called ‘crosstalk’ or ‘bleed- 
through’ of signal, that is, a false- positive reading in an 
adjacent channel. In general, four or five different colors 
can be imaged unambiguously with a general IF micro-
scope equipped with appropriate filters aligned with the 
peak absorption wavelengths. If more than four targets 
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Figure 4 Multiplex immunofluorescence (IF) using tyramide 
signal amplification (TSA)- based detection methods and 
multispectral imaging. Representative non- small cell lung 
carcinoma stained with six markers (cytokeratin (CK), 
programmed death- ligand 1 (PD- L1), programmed cell death 
protein-1 (PD-1), CD68, CD8, FOXP3). The image acquisition 
of all markers occurs simultaneously. Individual markers (or 
select combinations of markers) can then be displayed.
are to be imaged simultaneously, a multispectral imaging 
system that can conduct linear unmixing of signals is 
often required to separate the signals.5 Such systems 
can also have the advantage of subtracting both spectral 
overlap and tissue autofluorescence; however, they also 
require the preparation of a spectral library or the use of a 
synthetic library, as per manufacturer’s recommendation.
Assay optimization and validation
mIF panel development is essentially the consolidation 
of multiple singleplex IF protocols into a single protocol 
that shows an equivalent staining pattern relative to the 
optimized singleplex IF and IHC staining.5 Switching 
from the singleplex to multiplex format can lead to an 
increase or decrease of individual marker signals, poten-
tially requiring additional optimization of the antigen 
retrieval conditions (pH and temperature), reagent titra-
tion (primary antibody, secondary antibody, fluorophores, 
etc), incubation conditions (time and temperature), 
and blocking of non- specific binding. The sequential 
order of the targets to be tested can also impact assay 
performance. This is an important consideration when 
designing mIF panels and trouble- shooting any potential 
deviations from singleplex IHC or IF.5
In general, it is recommended to label more highly 
expressed targets with lower intensity fluorophores and 
vice versa. As a general recommendation and based 
on the expected kinetics of antibodies in solution, the 
starting incubation time for any primary antibody workup 
is generally for ~30 min between 18°C and 22°C (i.e. 
ambient temperature), while starting TSA fluorophore 
dilutions are typically around 1:100. These two indepen-
dent variables should be tested separately. Between cycles 
of primary antibody application, it is important to ensure 
complete antibody stripping from the previous cycle as 
well as complete antigen retrieval for the next cycle’s 
target of interest.
Because TSA reagents covalently bind to sites 
surrounding the antigen, they can potentially inhibit 
the binding of a subsequent primary antibody through 
steric hindrance. This is commonly termed ‘blocking’ 
or an ‘umbrella effect’. This tends to occur in situations 
where multiple markers reside in a single cell compart-
ment, such as a CD3+, CD8+, PD-1+ T cell, where all 
three markers are expressed on the cell membrane. It is 
possible that, if CD3 and/or CD8 come before PD-1 in 
the panel, sufficient tyramide will be deposited to block 
the PD-1 antigen. If present, this phenomenon can be 
identified when the comparison to singleplex IHC/IF is 
performed. A useful approach to determine antibody/
fluorophore interference or blocking is the drop controls 
method described by Surace et al., to find which one is 
causing the interference.57 Potential corrective actions 
then include increasing the primary antibody concen-
tration(s), reducing TSA fluorophore concentration(s), 
and/or changing the order of targets in the panel, among 
others.
Multispectral technologies require additional consid-
erations during optimization, such as the generation 
of a spectral library and balancing of signal intensities. 
The spectral library facilitates capture using the correct 
spectra from each fluorophore, thus allowing the discrim-
ination of individual signals.19 Generating an appropriate 
spectral library requires imaging single samples stained 
with only one fluorescent dye at a time with a primary 
antibody directed against well- known and highly preva-
lent antigens (e.g. CD20, cytokeratins, vimentin, CD3, 
etc). In multiplex panels, there is risk of bleedthrough 
from a high- intensity signal into the channel for a neigh-
boring low- intensity signal, leading to false positives. 
After the library is established, signal from exogenous 
and endogenous autofluorescence may also be extracted 
using these technologies.5
Panel development should ideally be performed using 
tissues with a full range of known expression patterns 
for the targets of interest. Once the panel is developed 
and validated, these same tissues can be run with each 
batch as additional controls. Final validation requires the 
performance of intrasite reproducibility studies. Intersite 
reproducibility studies will also be required as these tech-
nologies are employed in multi- institutional studies39 58 
and prior to clinical use.
Advantages
There are currently hundreds of commercially available 
purified fluorophores for which detection hardware is 
commonly available and, as such, fluorescence- based 
multiplex staining techniques are widely available. In 
general, four to five different carefully selected fluoro-
phores may be applied, and interrogation of the entire 
slide can be performed in a single round of imaging. When 
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Figure 5 Tissue- based mass spectrometry. Representative 
images from a 40- marker panel applied to human decidua 
and acquired using multiplexed ion beam imaging by time 
of flight. Six- color overlay (top left) and enlarged two- 
color insets (border) of a representative sampling of the 
simultaneously acquired markers.
multispectral microscopes are used, the number of fluo-
rophores applied to a single slide can be increased up to 
eight, and tissue autofluorescence can also be subtracted 
from the image. Most publications to date using this tech-
nology have reported 5–10 select ROIs per slide. ROIs 
can be tiled or stitched together to image the whole slide; 
however, this is currently time- and data- intensive, though 
technological advances in imaging whole slides in this 
manner are anticipated in the near future. In contrast 
to the chromogenic IHC approaches discussed above, IF 
has a larger linear dynamic range, facilitating studies of 
marker intensity. Cycled marker labeling approaches for 
mIF are also now being explored,54–56 which substantially 
increase the number of markers that could be quantified 
on a single slide.
Disadvantages
Imaging approaches that do not use multispectral tech-
nologies may be limited in their quantitative ability in 
some circumstances by tissue autofluorescence, while 
those that are multispectral require expensive, dedicated 
instrumentation and currently only image select ROIs. 
Many mIF approaches currently use TSA- based reagents, 
which, while quantitative, are driven by enzymatic amplifi-
cation. Amplification has the advantage of boosting signal 
intensity, however, there is also the risk of overactive tyra-
mide deposition, potentially contributing to an umbrella 
effect and/or signal bleed- through. Newer approaches 
that could potentially overcome this limitation include 
conjugating primary antibodies to DNA barcodes with 
subsequent detection using in situ- based polymerization 
and incorporation of fluorescent dNTP analogs.54 mIF is 
also considerably more time consuming compared with 
bright field in terms of assay development and subse-
quent digital pathology- related steps.
tissue-based mass spectrometry
Assay principles and workflow
Tissue- based mass spectrometry, also known as elemental 
mass spectrometry immunohistochemistry (EMS- IHC), 
or simply mass spectrometry immunohistochemistry 
(MS- IHC) is emerging as an important method to char-
acterize the spatial organization of proteins within 
biological samples.59–62 EMS- IHC has been used in recent 
work to shed light on autoimmune mechanisms in type 
1 diabetes,62 to define expressional features of marginal 
zone B cells,63 and to relate single cell phenotypes to tissue 
histology in the tumor microenvironment.61 In contrast 
to optical methods that quantify immunofluorescence 
or immunoperoxidase via fluorescent or chromogenic 
reporters, EMS- IHC detects elemental mass tags attached 
to primary antibodies directly in the tissue of interest. A 
single mastermix of all conjugated antibodies is used to 
stain a tissue section using a modified workflow similar 
to conventional IHC. After sample staining, the slide is 
introduced into the mass spectrometer. After a ROI is 
selected, the tissue within the selected region undergoes 
pixel- by- pixel ionization, where each portion of the ROI 
corresponding to a pixel in the final image is ionized 
in sequential fashion. The ions generated from each of 
these pixel measurements are subsequently analyzed 
using TOF mass spectrometry. The abundance of each 
elemental reporter extracted from the TOF spectra for 
each pixel is used to generate an image of the tissue. 
For a 40- marker staining panel, the resultant data would 
comprise 40 greyscale images where the pixel intensity 
in a given image corresponds to the abundance of the 
targeted antigen (figure 5).
There are currently two related approaches to perform 
EMS- IHC. The first is MIBI- TOF.1 In this approach, a 
charged ion beam (usually composed of O2
+) is directed 
at the sample in a vacuum chamber to generate secondary 
ions from the tissue. These secondary ions are extracted 
with an electric field and injected into the TOF for 
measurement. Imaging resolution with MIBI- TOF is an 
adjustable parameter where acquisition time and resolu-
tion can be traded with one another depending on the 
specific application. For example, an imaging resolution 
of 260 nm can be achieved, but the imaging time for 1 mm2 
of tissue is 27 hours. The fraction of the total tissue bulk 
that is consumed when imaging with MIBI- TOF is also 
adjustable, which permits a single field to be rescanned 
multiple times. The second approach is IMC.62 Although 
IMC also uses TOF to quantify the identified proteins, the 
ionization mechanism is distinct. In particular, it employs 
a high- intensity pulsed laser of fixed diameter to ablate 
the tissue in a single pass over the sample. The vaporized 
tissue is subsequently transported via helium carrier gas to 
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an argon inductively coupled plasma where the material 
is ionized prior to TOF analysis. Differences in how the 
sample is ionized result in corresponding differences in 
technical performance (Hyperion Imaging System, Flui-
digmTM), summarized in online supplementary figure 1.64 
Since a laser is used for ablation, the resolution is limited 
to about 1 µm.
Assay optimization and validation
The EMS- IHC workflow for reagent preparation and 
tissue staining is similar in many ways to other immunoas-
says. The epitope retrieval steps are the same as for tradi-
tional IHC (see ‘Standard chromogenic IHC’ section). 
The protein blocking step is also the same. However, 
EMS- IHC workflows do not use HRP for target visualiza-
tion. Thus, a peroxidase block is not necessary. Following 
blocking, slides are incubated with metal- conjugated 
primary antibodies. However, rather than staining with a 
single primary antibody, the entire mastermix of up to 40 
distinct antibodies is applied in one simultaneous step. 
Additionally, because the primary antibodies are directly 
conjugated with their respective metal isotopes, amplifi-
cation with enzymatic secondary antispecies antibodies is 
not required. The sensitivity of this technology compared 
with the benchmark of routine chromogenic IHC staining 
has yet to be determined.
Advantages
The spectral separation between reporter channels and 
the large number of unique elemental mass tags permits 
EMS- IHC to image dozens of proteins simultaneously in 
a single tissue section with minimal channel crosstalk.59 60 
This is in contrast to conventional IF, where tissue auto-
fluorescence and spectral overlap typically limit these 
assays to five to eight channels in routine use.35 65
Disadvantages
Thus far, both MIBI- TOF and IMC have been used 
primarily as research tools. Staff training and reagent opti-
mization for both platforms require significant time and 
expertise in IHC. Channel contamination with hydrides, 
oxides, hydroxides, and cyanides, as well as other isotopic 
impurities is possible, and needs to be recognized and 
compensated for. Before EMS- IHC can transition to 
more routine use, a few key technological advances will 
be necessary. Specifically, commercial availability of 
preformulated mastermixes containing a full antibody 
staining panel will be required to mitigate batch effects 
and permit tissue staining to be performed with existing 
autostainer platforms. Increased automation, including 
real time image autofocusing, sample autoloading, and 
more streamlined field selection will simplify operation 
and repeatability. Lastly, technical improvements that will 
increase the rate of pixel acquisition and efficiency of ion 
extraction are expected to increase sample throughput 
by an order of magnitude or more, permitting shorter 
turnaround times.
digital spatial profiling
Assay principles and workflow
DSP is served on a novel platform (GeoMxTM) that offers 
non- destructive, simultaneous high- plex quantitative 
measurement of proteins within specific ROIs. Two types 
of primary antibodies are used in this workflow: (1) high- 
plex primary antibodies linked to a DNA bar code tag via a 
UV- cleavable linkage for target interrogation; (2) primary 
antibodies conjugated with fluorophores to define up to 
four compartments to help select morphological regions 
for analysis. These antibodies are all applied to a FFPE 
slide following antigen retrieval, similar to other IHC- 
based methods. Using the GeoMx DSP, a whole slide 
image of the fluorescent antibodies is acquired. The 
fluorescent signal from this first step is strong enough 
that tissue autofluorescence is not a significant analytic 
concern. The user then selects ROI(s) within these 
compartments. A UV laser is then focused using a dual 
micro- mirror device, cleaving the tags from selected areas 
of the slide. Then, a small pipet is robotically directed to 
the ROI and it samples (or ‘sips’) 1–2 µL of liquid above 
the ROI that contains all of the cleaved DNA tags. These 
tags are transferred by a robot to a multiwell plate and 
counted using the NanoStringTM method with six fluo-
rescent barcodes.66 67 For example, a user could collect 
50 UV- tagged antibodies within a CD68- labeled compart-
ment. If there were three other fluor- labeled compart-
ments within the same ROI (e.g. CD8, cytokeratin, and 
DNA), the user could create 200 variables per ROI. While 
the user cannot see and count the number of macro-
phages or T cells, average levels of 50 proteins within 
the CD68+ macrophage compartment or CD8+ T cell 
compartment in the ROIs can be defined. Figure 6 illus-
trates the concept of molecular compartmentalization 
and shows how counts collected in each compartment 
are measured as independent variables and inform an 
understanding of spatial relationships, even though no 
associated image is produced.
Assay optimization and validation
Similar to previously discussed modalities, each antibody 
must be validated prior to selection. The antibodies used 
for DSP have to then be validated again after DNA tag 
labeling. Antibody validation as well as optimization (titra-
tion) of each antibody in the vendor- designed multiplex 
kits is conducted by the vendor (NanoStringTM). As with 
the aforementioned technologies, final multiplex assay 
performance should be assessed for potential deviations 
of marker detection from singleplex IHC or quantitative 
IF.68
Advantages
To date, DSP has been executed in the 40- plex range 
(limited by validated antibodies), but there are 800 
unique NanoStringTM barcodes, making it theoretically 
possible to perform an 800- plex assay. Perhaps even more 
interesting is the application of the technique for mRNA 
in situ detection. While there is little publicly available 
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box 1 Checklist for multiplex immunohistochemistry 
(IHC)/immunofluorescence (IF) assay optimization and 
validation: recommended information for inclusion in peer- 
reviewed manuscripts
1. Optimization of single stain IHC method for each target
 – Primary antibody selection.
 – Use and description of positive and negative controls for assay 
development. Ensure that for non- polymer- based amplification 
methods, concentration- matched isotype controls are negative.
 – Primary antibody and secondary reagent titrations to determine 
optimal signal- to- noise while maintaining sensitivity.
2. Combine all single IHC/IF assays into a multiplex panel and ensure 
staining levels of individual markers are still comparable to single 
stain IHC.
3. Perform and report reproducibility studies across multiple batches 
and multiple days.
4. Positive and negative controls for each marker should be run with 
each staining batch.
5. When switching the order of targets in mIF/mIHC panel, switching 
an antibody to a different fluorophore, or adding/removing an anti-
body from the panel, revalidation of the panel to singleplex IHC/IF 
should be performed.Figure 6 Digital spatial profiling. (A) A multiplex 
immunofluorescence image is first used to create molecular 
compartments. (B) The molecular compartments (green=CK, 
yellow=CD45, blue=CD68) are used to guide the UV laser 
and subsequent sipping process in this representative spot 
on a non- small cell lung carcinoma tissue microarray (TMA). 
(C) The amount of signal for a given marker is then assessed 
within a given compartment. Shown here is normalized CD8 
signal in the CD45 compartment (blue) and the remainder of 
the tissue, that is, non- CD45 compartment, (red) by tumor 
tissue spot number on the TMA.
data on assessing mRNA in situ using DSP, the high- plex 
capability, using mRNA probes with some level of redun-
dancy, could easily exceed 800.
Disadvantages
Unlike other methods of IHC or high- plex analysis of 
tissue, DSP cannot generate an image. Heat maps can be 
generated based on the ROIs selected, but the resolution 
of the heat map becomes prohibitively expensive if very 
small ROIs are used to tile a whole slide. The smallest 
region that can be selected is about 10 µm, so it is theo-
retically possible to select a single cell. More commonly, 
a ROI is selected representing an architectural region on 
a whole slide or a TMA spot. Although no image can be 
created, spatial definition can be achieved by manual or 
molecular selection of ROI, and then heat maps or ROI/
TMA spot calculations can be made that use the spatial 
localization as a variable. This results in spatially informed 
quantitative measurements.
COnClusIOns
In summary, there are a number of potential approaches 
to performing mIHC/IF on FFPE, each with distinct 
advantages and disadvantages. Many of these approaches 
may be considered complementary to each other. It is 
anticipated that some of the higher- plexing approaches 
will remain discovery tools for some time, while some 
of the relatively lower- plex approaches may be applied 
sooner in the clinic. Here, we present initial standards for 
both research scientists and laboratory experts focused on 
early clinical development. The fundamental principle 
for validating and optimizing each of the approaches 
described is that single chromogenic IHC assays are the 
starting point and reference for mIHC/mIF method 
development. In this principle, the final multiplex assay 
should be able to recapitulate the results obtained with 
each single IHC assay. This often takes considered optimi-
zation, with panel design requiring 1–4 months of effort, 
depending on the markers being interrogated. Key steps 
in mIHC/mIF assay development that are recommended 
for inclusion in peer- reviewed manuscripts are provided 
in box 1. Adherence to standards for mIHC/mIF assay 
will facilitate the development of biomarkers for immu-
notherapeutic regimens and ensure these emerging tech-
nologies achieve their diagnostic potential.
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